Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Accounts receivable (USD, thousands)

Other receivables (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Restricted cash (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Financing lease right-of-use asset (USD, thousands)

Long-term investments (USD, thousands)

Deferred offering costs (USD, thousands)

Other long-term assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses (USD, thousands)

Current portion of operating lease liabilities (USD, thousands)

Current portion of financing lease liability (USD, thousands)

Other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Operating lease liabilities, net of current portion (USD, thousands)

Financing lease liability, net of current portion (USD, thousands)

Simple agreements for future equity (SAFEs) (USD, thousands)

Other non-current liabilities (USD, thousands)

Total liabilities (USD, thousands)

Series A convertible preferred stock (USD, thousands)

Series B convertible preferred stock (USD, thousands)

Preferred stock, $0.0001 par value (USD, thousands)

Common stock, $0.0001 par value (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated other comprehensive income (loss) (USD, thousands)

Accumulated deficit (USD, thousands)

Total stockholders’ equity (deficit) (USD, thousands)

Total liabilities, convertible preferred stock and stockholders’ equity (deficit) (USD, thousands)

2200e61304ad67bf93fe5cffabc2aff34fb246a80989a04a5c49d2f75d5a84a7

Number of partnered target programs with Merck (count)

AlloNK dose in company-sponsored trials (billion cells)

5c599bd944a8c34dd91a0ba7403d766e78162023278e109c1a859777232bfa60

Collaboration Revenue (USD, thousands)

License and Development Support Revenue (USD, thousands)

Total Revenue (USD, thousands)

Research and Development Expenses (USD, thousands)

General and Administrative Expenses (USD, thousands)

Total Operating Expenses (USD, thousands)

Income (Loss) from Operations (USD, thousands)

Interest Income (USD, thousands)

Change in Fair Value of SAFEs (USD, thousands)

Other Income (Expense), Net (USD, thousands)

Total Other Income (Expense), Net (USD, thousands)

Loss Before Provision for Income Taxes (USD, thousands)

Provision for Income Taxes (USD, thousands)

Net Income (Loss) (USD, thousands)

Net Income (Loss) Per Share, Basic and Diluted (USD)

Weighted-Average Common Shares Outstanding, Basic and Diluted (shares)

Unrealized Gain (Loss) on Investments, Net (USD, thousands)

Comprehensive Income (Loss) (USD, thousands)

dcc25fc59fe71a0ce79d4b583442413688942e1f19c1559ca6acbaa44afdd852

Net loss (USD, thousands)

Depreciation and amortization (USD, thousands)

Stock-based compensation (USD, thousands)

Change in fair value of SAFEs (USD, thousands)

Accretion of discounts and amortization of premiums on investments, net (USD, thousands)

Accounts receivable change (USD, thousands)

Other receivables change (USD, thousands)

Prepaid expenses and other current assets change (USD, thousands)

Other long-term assets change (USD, thousands)

Accounts payable change (USD, thousands)

Accrued expenses change (USD, thousands)

Operating lease right-of-use asset and lease liabilities, net change (USD, thousands)

Net cash used in operating activities (USD, thousands)

Purchases of property and equipment (USD, thousands)

Purchases of investments (USD, thousands)

Maturities of investments (USD, thousands)

Net cash provided by investing activities (USD, thousands)

Proceeds from issuance of common stock, net of commissions (USD, thousands)

Proceeds from exercise of stock options (USD, thousands)

Proceeds from purchase of ESPP shares (USD, thousands)

Payments on finance leases (USD, thousands)

Cash paid in connection with IPO offering costs (USD, thousands)

Net cash provided by financing activities (USD, thousands)

Net increase (decrease) in cash, cash equivalents and restricted cash (USD, thousands)

Cash, cash equivalents and restricted cash at beginning of period (USD, thousands)

Cash, cash equivalents and restricted cash at end of period (USD, thousands)

b289059f21f1cdc0a1caed4a7f7174889c72186002cd73d073de3539789e3619

Collaboration Revenue

- Merck Collaboration Agreement

License and Development Support

- AB-201 Agreement

Total Revenue

880009f49742079874459ee4e7173b54b469ed2873cf5ed377e3d4025b36e11a

Artiva Biotherapeutics (ARTV)

Financials